# FDA 483 - ImClone Systems, LLC - July 27, 2023

Source: https://www.globalkeysolutions.net/records/483/imclone-systems-llc/0d2a8fea-1c80-4ade-b168-ced9cbf6b5aa

> FDA 483 for ImClone Systems, LLC on July 27, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: ImClone Systems, LLC
- Inspection Date: 2023-07-27
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Documents

- [483 - 2022-08-22](https://www.globalkeysolutions.net/records/483/imclone-systems-llc/ebff6286-339c-4794-af15-df4b3deeff8b)
- [483 - 2019-11-26](https://www.globalkeysolutions.net/records/483/imclone-systems-llc/f91880cc-3d62-424e-b9e4-64156b5db998)
- [483 - 2019-11-26](https://www.globalkeysolutions.net/records/483/imclone-systems-llc/47cd6878-6a5e-4876-9ce7-aee2c4c2cbc1)
- [483 - 2019-11-26](https://www.globalkeysolutions.net/records/483/imclone-systems-llc/ae1b1bac-061f-4570-b184-9b382ec3c67f)
- [483 - 2022-08-25](https://www.globalkeysolutions.net/records/483/imclone-systems-llc/bb047a85-d942-468f-ba8c-12d4c36b0558)

## Related Officers

- [Charles Luan-Chia Kuo, Staff Fellow](https://www.globalkeysolutions.net/people/charles-luan-chia-kuo-staff-fellow/038269f6-aa8e-46f1-bb93-a5e1ae277d6e)
- [Samuel Mindaye, Lead Interdisciplinary Scientist](https://www.globalkeysolutions.net/people/samuel-mindaye-lead-interdisciplinary-scientist/2f50f059-06b1-49cf-a19f-05f7fec4e107)
- [Thuy Nguyen, BMB1 Chief, Wayne Seifert, CSO](https://www.globalkeysolutions.net/people/thuy-nguyen-bmb1-chief-wayne-seifert-cso/b27d24c5-4cf6-44e9-9294-a8be24b70d49)
- [Leiyun Boone, Biologist, Aditi Thakur, Chemist](https://www.globalkeysolutions.net/people/leiyun-boone-biologist-aditi-thakur-chemist/e6c4a15f-2493-47c6-b0d6-c9745f09c802)

Company: https://www.globalkeysolutions.net/companies/imclone-systems-llc/ccde4edf-e0cb-4367-a935-725ce0bad4d3

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd